Table 2 The survival outcome of different doses of pyrotinib or pyrotinib plus capecitabine in the phase I trials

The entire cohort

66

9.2(5.4–12.9)

31.0(16.5–45.5)

Pyrotinib

38

8.2(5.6–10.9)

27.1(21.6–32.5)

Pyrotinib 80 mg

3

5.5

15.5

Pyrotinib 160 mg

8

7.3

25.7

Pyrotinib 240 mg

8

3.3

13.1

Pyrotinib 320 mg

9

7.3

25.5

Pyrotinib 400 mg

8

13.7

41.9

Pyrotinib 480 mg

2

1.4

8.8

Pyrotinib +capecitabine

28

22.1(14.3–29.9)

37.4(12.2–62.7)

Pyrotinib 160 mg + capecitabine

3

26.1

60.1

Pyrotinib 240 mg + capecitabine

3

6.9

23.6

Pyrotinib 320 mg + capecitabine

11

16.4

27.6

Pyrotinib 400 mg + capecitabine

11

29.9

59.9